Brickwood Asset Management’s Pfizer PFE Stock Holding History

Brickwood Asset Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-27,074	Closed	-$760K	–	12
2026 Q1	$760K	Buy	27,074 +905	+3%	+$24.1K	0.57%	8
2025 Q4	$652K	Buy	26,169 +4,670	+22%	+$118K	0.45%	7
2025 Q3	$548K	Buy	21,499 +4,155	+24%	+$103K	0.38%	9
2025 Q2	$307K	Buy	+17,344	New	+$404K	0.23%	7

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Brickwood Asset Management's PFE Position: Q2 2026 in Review

Brickwood Asset Management sold out of Pfizer (PFE) in Q2 2026, closing a stake of 27,074 shares — an estimated $760K sold.

Brickwood Asset Management first reported a position in PFE in Q2 2025 and held it in 4 quarters. The position peaked at $760K in Q1 2026. 2,817 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Brickwood Asset Management reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
Brickwood Asset Management sold 27,074 Pfizer shares in Q2 2026, an estimated $760K.
Brickwood Asset Management first reported a position in Pfizer in Q2 2025 and held it in 4 quarters.
Brickwood Asset Management's Pfizer position peaked at $760K in Q1 2026.
2,817 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Brickwood Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.